Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Microfluidics International Corporation Appoints Thomai Panagiotou, PhD to Chief Technology Officer

Abstract:
Microfluidics International Corporation (OTCBB: MFIC) today announced that Dr. Thomai "Mimi" Panagiotou has been promoted to the position of Chief Technology Officer. Dr. Panagiotou previously held the position of Vice President of Research and Development.

Microfluidics International Corporation Appoints Thomai Panagiotou, PhD to Chief Technology Officer

NEWTON, MA | Posted on July 23rd, 2008

In this role, Dr. Panagiotou will assume responsibility for the overall direction of the Company's technology and lead Microfluidics' research and development initiatives. Central to these activities will be the ongoing development and expansion of the Company's proprietary Microfluidics Reaction Technology (MRT) which enables the optimal and consistent production of nanomaterials at smaller sizes not achievable using conventional processing methods. Dr. Panagiotou will also be charged with identifying innovative new product and technology opportunities both internally and in collaboration with strategic university and business partners. Dr. Panagiotou will report to Michael C. Ferrara, Chief Executive Officer of Microfluidics International Corporation.

"Since Mimi joined Microfluidics five years ago, she has played a leading role in advancing the Company's technology, including establishing the Microfluidics Technology Center to broaden our application across various industries and the initial development of both MRT and our plug and play machine technology platform," said Michael C. Ferrara. "Mimi's scientific expertise, her depth of industry experience and her extensive understanding of our technology and products will be important to our growth efforts as we focus on building and leveraging a robust, dynamic product portfolio."

Dr. Panagiotou received her PhD in Mechanical Engineering from Northeastern University. She has published and presented extensively in major scientific journals and international conferences in the areas of nanoencapsulation, crystallization, drug delivery, nanomaterial processing and Process Intensification. Dr. Panagiotou joined Microfluidics in 2003 as Director of Research and Development and was promoted to Vice President of Research and Development in 2005. Prior to joining Microfluidics, Dr. Panagiotou was a Manager at Arthur D. Little and TIAX LLC, and a Principal Engineer at Physical Sciences, Inc. In her previous work experience, she has provided technical leadership across a variety of projects including a multi-million dollar pulmonary insulin delivery project, the development of drug eluting coatings for stents and self healing coatings for vascular grafts. Dr. Panagiotou is also the inventor of methods and hardware to produce polymer microspheres and coatings for stents that led to the award of two patents.

####

About Microfluidics International Corporation
Microfluidics International Corporation designs, manufactures and distributes proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics applies its more than 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics’ equipment customers.

Forward-Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to our plan to achieve, maintain and/or increase growth in revenue and/or market share, to achieve, maintain, and/or increase operating profitability, and/or to achieve, maintain, and/or increase net operating profitability. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by us to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to, the following risks and uncertainties: (i) whether the performance advantages of our Microfluidizer materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the timing of orders will significantly affect quarter to quarter revenues and resulting net income results for a particular quarter, which may cause increased volatility in our stock price, (iii) whether we will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to our ability to maintain compliance with the covenants and terms of our loan agreement with our senior lender, (iv) whether our Microfluidics Reaction Technology will be adopted by customers as a means of producing innovative materials in large quantities, (v) whether we are able to deploy prototype Microfluidics Reaction Technology systems for nanoparticle production and then manufacture and introduce commercial production Microfluidics Reaction Technology equipment, and (vi) whether we will achieve a greater proportion of our sales in the future through the sale of advanced processor production systems.

Contacts:
Microfluidics International Corporation
Brian E. LeClair
617-969-5452
or
FD Ashton Partners
Michael Cummings
617-897-1532

Copyright © Microfluidics International Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Microfluidics/Nanofluidics

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

Heat-Based Technique Offers New Way to Measure Microscopic Particles March 13th, 2014

New partnership between Malvern Instruments and RheoSense brings m-VROCi to industrial markets February 28th, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE